EUVIMEDEUVIMED entdecken
Crossref

Dose-Finding and Efficacy Confirmation Trial of the Superselective Intra-arterial Infusion of Cisplatin and Concomitant Radiation Therapy for Locally Advanced Maxillary Sinus Cancer (JCOG1212): Results of the Efficacy Confirmation Phase in Patients with T4aN0M0

Akihiro Homma, Masashi Mikami, Kazuto Matsuura, Rikiya Onimaru, Daisuke Yoshida, Hirotaka Shinomiya, Akira Ohkoshi, Ryuichi Hayashi, Yuki Saito, Hiroyuki Tachibana, Kiyoto Shiga, Tsutomu Ueda und 4 weitere

International Journal of Radiation Oncology*Biology*Physics · 2024-04 · 118 (5) · 1271-1281

DOI: 10.1016/j.ijrobp.2023.11.031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024-04. Verfasst von Akihiro Homma und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Hospital, Sapporo, Japan. Electronic address: ak-homma@med.hokudai.ac.jp. Hauptthemen laut MEDLINE: Maxillary Sinus Neoplasms, Antineoplastic Agents, Head and Neck Neoplasms. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: National Cancer Center, Japan Agency for Medical Research and Development, Ministry of Health, Labour and Welfare.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Locally advanced maxillary sinus cancers require radical surgery as a standard treatment, but this often results in significant disfigurement and impairment of function. JCOG1212 seeks to evaluate the safety and efficacy of the superselective intra-arterial infusion of cisplatin and concomitant radiation therapy (RADPLAT) for T4aN0M0 and T4bN0M0 maxillary sinus squamous cell carcinomas. We herein report the results of the efficacy confirmation phase in the T4a cohort. METHODS AND MATERIALS: Patients received 100 mg/m2 cisplatin intra-arterially weekly for 7 weeks with concomitant radiation therapy (total 70 Gy) as determined by the results of the preceding dose-finding phase. The trial aimed to evaluate the primary endpoint of 3-year overall survival (OS), comparing RADPLAT with the historical control for 3-year OS in surgery (80%). RESULTS: From April 2014 to August 2018, 65 patients were registered in the T4a cohort from 18 institutions, consisting of 54 men and 11 women with a median age of 64 years (range, 40-78 years) and Eastern Cooperative Oncology Group performance status 0/1 (58/7). After excluding 1 ineligible patient, 64 patients were included in the primary analysis of efficacy and safety. The median follow-up was 4.5 years in all eligible patients, and the primary endpoint for 3-year OS was 82.8% (90% CI, 73.4%-89.2%). With regard to acute adverse events, mucositis (grade ≥3), neutropenia (grade ≥3), increased creatinine (grade ≥2), hearing impairment (grade ≥2), and stroke (grade ≥2) were observed in 20.3%, 14.1%, 3.1%, 3.1%, and 1.6% of patients, respectively. One treatment-related death due to a thromboembolic event was reported. CONCLUSIONS: We demonstrated that RADPLAT showed favorable results for patients with T4aN0M0 maxillary sinus squamous cell carcinomas compared with the historical control for 3-year OS in surgery, which was from an earlier period, and showed some specific toxicities. Therefore, RADPLAT, as well as surgery, can be regarded as a possible treatment option for these patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Maxillary Sinus NeoplasmsAntineoplastic AgentsHead and Neck NeoplasmsMaleHumansFemaleAdultMiddle AgedAgedCisplatinInfusions, Intra-ArterialMaxillary SinusTreatment OutcomeChemoradiotherapySquamous Cell Carcinoma of Head and Neck

Substanzen

CisplatinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, Hokkaido University Hospital, Sapporo, Japan. Electronic address: ak-homma@med.hokudai.ac.jp.
  • Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa, Japan.
  • Department of Radiation Oncology, Tonan Hospital, Sapporo, Japan.
  • Department of Diagnostic and Interventional Radiology, Hokkaido University Hospital, Sapporo, Japan.
  • Department of Otolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.

Förderung

  • National Cancer Center
  • Japan Agency for Medical Research and Development
  • Ministry of Health, Labour and Welfare

Zitieren

APA

Homma, A., Mikami, M., Matsuura, K., Onimaru, R., Yoshida, D., Shinomiya, H., Ohkoshi, A., Hayashi, R., Saito, Y., Tachibana, H., Shiga, K., Ueda, T., Uemura, H., Nakamura, K., Fukuda, H., & Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG) (2024). Dose-Finding and Efficacy Confirmation Trial of the Superselective Intra-arterial Infusion of Cisplatin and Concomitant Radiation Therapy for Locally Advanced Maxillary Sinus Cancer (JCOG1212): Results of the Efficacy Confirmation Phase in Patients with T4aN0M0. International Journal of Radiation Oncology*Biology*Physics, 118(5), 1271-1281. https://doi.org/10.1016/j.ijrobp.2023.11.031

Vancouver

Homma A, Mikami M, Matsuura K, Onimaru R, Yoshida D, Shinomiya H, et al. Dose-Finding and Efficacy Confirmation Trial of the Superselective Intra-arterial Infusion of Cisplatin and Concomitant Radiation Therapy for Locally Advanced Maxillary Sinus Cancer (JCOG1212): Results of the Efficacy Confirmation Phase in Patients with T4aN0M0. International Journal of Radiation Oncology*Biology*Physics. 2024;118(5):1271-1281. doi:10.1016/j.ijrobp.2023.11.031

BibTeX
@article{Homma2024,
  author = {Homma, Akihiro and Mikami, Masashi and Matsuura, Kazuto and Onimaru, Rikiya and Yoshida, Daisuke and Shinomiya, Hirotaka and Ohkoshi, Akira and Hayashi, Ryuichi and Saito, Yuki and Tachibana, Hiroyuki and Shiga, Kiyoto and Ueda, Tsutomu and Uemura, Hirokazu and Nakamura, Kenichi and Fukuda, Haruhiko and Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG), Head and Neck Cancer Study Group of the Japan Clinical Oncology Group (JCOG-HNCSG)},
  title = {Dose-Finding and Efficacy Confirmation Trial of the Superselective Intra-arterial Infusion of Cisplatin and Concomitant Radiation Therapy for Locally Advanced Maxillary Sinus Cancer (JCOG1212): Results of the Efficacy Confirmation Phase in Patients with T4aN0M0},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2024},
  volume = {118},
  number = {5},
  pages = {1271--1281},
  doi = {10.1016/j.ijrobp.2023.11.031}
}
Kostenlos starten →